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A B S T R A C T
No previous event-related potentials (ERPs) study has explored the error-related negativity (ERN) - an ERP
component indexing performance monitoring - associated to cancer and chemotherapy-induced cognitive im-
pairment in a lung cancer population. The aim of this study was to examine differences in performance mon-
itoring in a small-cell lung cancer group (SCLC, C+) 1-month following chemotherapy and two control groups: a
non-small cell lung cancer patient group (NSCLC, C−) prior to chemotherapy and a healthy control group (HC).
Seventeen SCLC (C+) underwent a neuropsychological assessment and an ERP study using a flanker and a
stop-signal paradigm. This group was compared to fifteen age-, gender- and education-matched NSCLC (C−)
and eighteen HC.
Between 20 and 30% of patients in both lung cancer groups (C+ and C−) met criteria for cognitive im-
pairment. Concerning ERPs, lung cancer patients showed lower overall hit rate and a severe ERN amplitude
reduction compared to HC.
Lung cancer patients exhibited an abnormal pattern of performance monitoring thus suggesting that che-
motherapy and especially cancer itself, may contribute to cognitive deterioration. ERN appeared as an objective
laboratory tool sensitive to cognitive dysfunction in cancer population.
1. Introduction
Chemotherapy-induced cognitive impairment or ‘chemobrain’ is a
well-recognized clinical syndrome, consisting of subtle to moderate
cognitive changes across various domains (Jim et al., 2012). Although
acute cognitive changes during chemotherapy are common (Ahles
et al., 2002), long-term cognitive changes post-treatment seem to per-
sist only in a subgroup (17–34%) of cancer survivors (Jim et al., 2012;
Ahles and Saykin, 2007). In addition, cognitive deficits have also been
described in cancer patients prior to chemotherapy (Ahles and Saykin,
2002). In recent years, several studies using neuroimaging techniques,
concretely magnetic resonance imaging (MRI) and positron emission
tomography, as well as event-related brain potentials (ERPs), have re-
ported structural and functional changes associated with cancer and
chemotherapy (Simo et al., 2015; Kaiser and Dietrich, 2014).
The fined-grained analysis of electrophysiological measures (such as
ERPs), widely used in cognitive neuroscience, allows us to functionally
characterize certain cognitive processes with higher temporal precision
when compared to other metabolic based neuroimaging techniques
(Münte et al., 2001; Marco-Pallares et al., 2009). However, ERPs have
been scarcely used to investigate the neural correlates underlying
cancer and chemotherapy-related cognitive impairments (see for a re-
view, Kaiser and Dietrich (2014)). Most of the ERPs studies focused on
cancer population yielded converging evidence of changes in the well-
known P300 attention-related component associated with che-
motherapy (Kreukels et al., 2005; Kreukels et al., 2006; Kreukels et al.,
2008a; Kreukels et al., 2008b; Heukrodt et al., 1988; Kam et al., 2016).
More specifically, these studies showed a reduced amplitude and a
prolonged latency for the P300 component in chemotherapy-treated
patients, suggesting impairments of cognitive function including at-
tention and slow information processing and none of them included a
cancer control group prior to receive chemotherapy to study more
general cancer-related changes (Kreukels et al., 2005; Kreukels et al.,
2006; Kreukels et al., 2008a; Kreukels et al., 2008b; Heukrodt et al.,
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1988; Kam et al., 2016).
Cognitive impairments in performance monitoring can also be as-
sessed focusing on other stimulus-triggered ERP components, such as
the frontocentral N200 and the P300 components observed after the
presentation of the stimulus array. The amplitude of the N200 com-
ponent is larger in conflict-related or incongruent trials and it has been
associated to conflict monitoring (Gehring et al., 1992; Yeung et al.,
2004; van Veen and Carter, 2002b; Kopp et al., 1996). Some authors
have proposed that the conflict N2 component and the ERN share si-
milar neural generators (Burgess et al., 2000; Stuss et al., 1995;
Damasio, 1995; Holroyd and Coles, 2002). Besides, in incongruent
trials, this N2 component is followed by a delayed P300 peak latency,
which has been associated to a slowing of stimulus evaluation processes
in incongruent trials (Münte et al., 2001; Gehring et al., 1992; Kok,
1997). Finally, it is important to mention that the amplitude of the
P300 component has been associated to cognitive and executive func-
tions including attention, amount of resources involved in a particular
task and context updating in tasks that require stimulus evaluation and
memory updating (Münte et al., 2001; Kok, 1997; Ferdinand et al.,
2015).
The error monitoring is the ability to control our performance as
well as to correct our errors in a highly flexible manner and is part of
the executive function system (or cognitive control network), which
includes planning, problem solving, working memory, and performance
monitoring, among other regulatory functions (Burgess et al., 2000;
Stuss et al., 1995; Damasio, 1995). The ERN, with a very specific frontal
central scalp distribution, is elicited immediately after the detection of
a performance error (with a latency in between 60 and 100 ms after
error commission) and it is originated most probably in the anterior
cingulate cortex (ACC) (Holroyd and Coles, 2002; Marco-Pallares et al.,
2008; Gehring and Knight, 2000; Ullsperger and von Cramon, 2001;
Ridderinkhof et al., 2004). The functional aspects of the ERN has been
linked to reinforcement learning processes regulated by the mesence-
phalic dopaminergic system (Holroyd and Coles, 2002). To the best of
our knowledge, no previous ERP study in cancer population has ex-
plored this relevant neurophysiological marker associated to error
monitoring process.
Interestingly, one of the most important cognitive domains in which
changes due to chemotherapy have been described (see for a review Jim
et al. (2012)) is executive functioning. Most of the investigations on
chemotherapy and cancer-related cognitive changes have focused on
breast cancer patients whilst research focused on lung cancer popula-
tion has been scarce. Early studies found that lung cancer patients ex-
hibit cognitive impairments soon after chemotherapy treatment (Kaasa
et al., 1988a; Kaasa et al., 1988b; Komaki et al., 1995; Grosshans et al.,
2008). However, more recent studies have shown that lung cancer
population exhibit cognitive impairments not only following che-
motherapy but also prior to chemotherapy (cancer effect), accompanied
by structural and functional neural changes (Simo et al., 2015; Simo
et al., 2016; Horky et al., 2014; Simo et al., 2017). Thus, the study of
the toxic effects of cancer and chemotherapy on cognition in lung
cancer population remains challenging and under-represented in the
literature.
Based on previous studies pointing out the inherent problems in
cognitive control of lung cancer patients, we hypothesized that both
lung cancer groups (C+ and C– groups) will show a disruption in the
performance monitoring system as measured using the ERN component.
We further investigated the frontocentral N2 and P300 components as
additional measures of conflict monitoring (concurrent activation of
multiple-competing responses in incongruent trials). For this purpose,
we used a well-known paradigm that combines a flanker and a stop-
signal paradigm (measuring motor inhibition), which has been widely
used to investigate performance monitoring (Rodriguez-Fornells et al.,
2002; U.M. Kramer et al., 2007). This paradigm is well-suited in this
particular case, since it allows the observation of error monitoring
during stop-inhibited trials (i.e., patients cannot avoid responding), a
condition that induces a large amount of errors.
2. Methods
2.1. Patients
Patients were prospectively recruited from December 2010 to
December 2013 from the Lung Cancer Unit of the ICO L'Hospitalet-
Hospital Universitari de Bellvitge (n = 32). Patients were eligible if
they presented histologically proven diagnosis of either NSCLC or SCLC,
were between the ages of 40 and 70 years, had no severe concomitant
systemic illness or psychiatric disorder with a negative impact on
cognitive function, or had no other contraindication to undergo an MRI
scan. Patients were excluded if they had evidence of brain metastases
on MRI. This cross-sectional analysis is the baseline analysis of a
longitudinal study designed to examine the effects of further prophy-
lactic cranial irradiation (PCI) in SCLC patients (Simo et al., 2015). C+
(n = 17) who were eligible to receive PCI and were anti-HU negative
were enrolled one month following completion of chemotherapy but
prior to receive PCI. C– (n = 15) who were eligible to receive a pla-
tinum-based chemotherapy were enrolled in the study just after cancer
diagnosis and before the initiation of chemotherapy. NSCLC was se-
lected as the cancer control group because they underwent the same
platinum-based chemotherapy as SCLC patients but they would not
receive PCI, therefore facilitating the study of the long-term effects of
chemotherapy in the longitudinal study. Age- and education-matched
HC (n = 18) who met the same inclusion (except for cancer diagnosis)
and exclusion criteria were recruited through community advertise-
ments. Vascular risk factors were collected and classified in low-risk (if
the patient had none or one risk factor) and high-risk (if the patient had
two or more risk factors) groups (Welzel et al., 2008). The study pro-
tocol was approved by the Ethical Committee of Hospital Universitari
de Bellvitge-ICO L'Hospitalet and written informed consent was ob-
tained from all participants. All methods were performed in accordance
with relevant guidelines and regulations.
2.2. Neuropsychological assessment
Patients were evaluated using: Mattis Dementia Rating Scale–2
(MDRS-2); selected subtests of the Spanish version of the Wechsler
Adult Intelligence Scale-III (Vocabulary, Information, Similarities, Digit
Span, Letter Number Sequencing, Block Design, Matrix Reasoning, and
Picture Completion); Rey Auditory Verbal Learning Test (RAVLT);
Wechsler Memory Scale–III Logical Memory I–II; Rey-Osterreith
Complex Figure Test Copy, Immediate and Delayed; Spanish Version of
the Boston Naming Test; Verbal Fluency test (Phonemic and Semantic);
Trail Making Test (A–B); and Beck Depression Inventory (BDI).
Intelligence quotient was estimated using Vocabulary performance.
Raw cognitive test scores were compared with the validated Spanish
normative values, corrected for age and education, and converted into
z-scores. Cognitive impairment was defined as a MDRS-2 raw score<
123 (Mattis, 1988), one test ≥2 or two tests ≥1.5 standard deviations
below the sample mean (Correa et al., 2013). All statistical analyses
were conducted in SPSS 18.0 (SPSS, Chicago, IL). One-way analysis of
variance and Chi-square tests were used to test group differences with a
critical p-threshold of 0.05. Results are reported both uncorrected and
Bonferroni corrected for multiple comparisons.
2.3. Paradigm
Our paradigm was a modified variant of the Eriksen flanker task
(Eriksen and Eriksen, 1974) which has been previously used and de-
scribed in U.M. Kramer et al. (2007). Briefly, in go trials, the task re-
quired the participants to respond to the central arrow in an array of
five horizontal arrows, with the right hand after a right-directed arrow
and vice versa. The four surrounding arrows could either be compatible
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(33.3% of trials) or incompatible (50% of trials) to the central arrow.
Following a variant of the stop-signal paradigm (Band et al., 2003), the
remaining 16.6% of the trials were ‘no-go’ trials, where the inhibition of
the response was required after the central green arrow changed to red
after a variable delay. The stop-signal delay was initially set to 140 ms
and after a successful (or failed) inhibition the stop-signal delay in-
creased (or decreased) by 10 ms, making the inhibition harder (or ea-
sier) (Band and van Boxtel, 1999).
The stop-signal reaction time (SSRT) was computed by subtracting
the participant's mean stop-signal delay from the median reaction time
of correct ‘go’ responses (Band et al., 2003). They were encouraged to
correct their errors in the ‘go’ trials as fast as possible. The experiment
was divided in eight blocks, each comprising 240 trials, resulting in a
total of 1920 trials.
2.4. Neurophysiological study
2.4.1. Behavioral analysis
The percentage of correct responses was analyzed by a one-way
ANOVA on ‘group’ (HC, C+, C−). During all the analyses, in case a
main effect of ‘group’ was found, post-hoc tests were performed to
evaluate which group yielded different results. Levene's tests were
performed to test for equality of variances and if the assumption of
homogeneity of variances was met, Tukey's HSD (honest significant
difference) tests were conducted. On the contrary, if the variance was
not equally distributed, Games Howell post hoc tests were conducted.
The percentage of errors were analyzed by a two-way mixed-model
ANOVA with repeated measurement on the between-subjects variable
‘group’ and the within-subjects variable ‘compatibility’ (compatible,
incompatible). In addition, the percentage of corrected errors was
analyzed by a one-way ANOVA on group. Reaction time (RT) was de-
fined as the time between stimulus onset and the button press. The RT
was analyzed by a two-way ANOVA on ‘group’ and ‘response’ (correct
response, error) and the RT of correct responses was investigated by an
ANOVA on ‘group’ and ‘compatibility’. The RT of corrected errors was
analyzed by a two-way ANOVA on ‘group’ and ‘condition’ (corrected,
non-corrected). Lastly, post error slowing, post non-inhibited slowing
and SSRT were analyzed with a one-way ANOVA on ‘group’, provided
that the participant reached a minimum of 5 trials per condition in
order to compute a reliable average.
2.4.2. EEG recording and analysis
The electroencephalogram (EEG) was recorded from 29 tin elec-
trodes mounted in an elastic cap (electrode positions: Fp1/2, F3/4, C3/
4, P3/4, O1/2, F7/8, T3/4, T5/6, FC1/2, FC5/6, CP1/2, CP5/6, PO1/2,
Fz, Cz, Pz) with reference electrodes placed on the right and left mas-
toids. During the recording, all scalp electrodes were referenced against
an average reference, and electrode impedances were kept below 5 kΩ.
Vertical eye movements and blinks were monitored by an electrode
placed below the right eye. EEG and electrooculogram (EOG) were
recorded continuously and digitized with a sampling rate of 250 Hz
(bandpass from 0.01–70 Hz). EEG data was analyzed using EEGLAB
v13.4.4b (Delorme and Makeig, 2004) and custom routines written in
MatLab R2008b (The Mathworks, Natick, MA, USA). ERP data was re-
referenced off-line to the average of both mastoids (Luck, 2005) and
filtered with a 30 Hz low-pass. Trials with base-to-peak EOG amplitude
of> 75 μV, amplifier saturation, or a baseline shift exceeding 200 μV/s
were automatically rejected (Cunillera et al., 2008). After in-
dividualized rejection of artifacts, stimulus- and response-locked
averages were obtained for the different conditions. To obtain reliable
averages, we required each condition to have a minimum of 15 trials
per participant (Rodriguez-Fornells et al., 2002; Gurtubay-Antolin and
Rodriguez-Fornells, 2017; Gurtubay-Antolin et al., 2015).
2.4.3. ERPs: response-locked data
For the response-locked averages and after rejection of eye and
muscle artifacts, epochs of 200 ms before and 600 ms after the response
were extracted from the continuous EEG and baseline-corrected using a
−50–0 ms pre-response window following previously methodology
(Rodriguez-Fornells et al., 2002; U.M. Kramer et al., 2007; Gurtubay-
Antolin and Rodriguez-Fornells, 2017). In a similar manner as done by
U.M. Kramer et al. (2007), after visually inspecting the 30 Hz low-pass
filtered data, we decided to bandpass-filter (2–8 Hz) the EEG in order to
obtain the response-locked ERPs in the band in which the ERN is best
detectable. In the following, errors in ‘go’ trials will be referred to as
‘choice errors’ or Choice ERN and errors in ‘no-go’ trials will be referred
to as ‘stop errors’ or Stop ERN. To note, corrected and uncorrected
choice errors were included in the ‘choice error’ condition, since the
number of uncorrected and corrected choice errors separately did not
meet the criterion of a minimum of 15 trials in all the participants.
In ‘go’ trials, the amplitude of the error-related negativity in choice
errors (Choice ERN) was defined as the mean voltage in the 50–150 ms
interval following erroneous responses at the frontal and central mid-
line electrodes (Fz, Cz). The same time interval and location was used to
quantify the correct response amplitude (Choice Correct-related
Negativity or CRN), following the emission of correct responses.
To analyze ‘no-go’ trials, the amplitude of the ERN in stop errors
(Stop ERN) was measured between 100 and 200 ms after the non-in-
hibited response. In order to compare the amplitude of stop errors with
the amplitude of correct responses, stop CRN, was defined as the mean
voltage in the 100–200 ms interval following the emission of the correct
response. These temporal windows corresponded to the maximum
amplitude intervals (see panel A, Figs. 1 and 2). In ‘go’ trials, we sub-
mitted choice CRN and choice ERN amplitude values to a three-way
repeated-measures ANOVA that included the between-subject variable
‘group’ and two within-subject factors: ‘response’ (Correct: choice CRN,
error: choice ERN) and ‘electrode’ (Fz, Cz). In case a main effect of
‘group’ was found, post-hoc Tukey tests were conducted. In ‘no-go’
trials, we submitted the stop CRN and the stop ERN amplitudes to the
same three-way repeated-measures ANOVA.
2.4.4. ERPs: stimulus-locked data
In order to show that any reported group differences were not due to
the general effects of medication, we analyzed the exogenous N1 and P2
components (where we did not expect to find between-group differ-
ences). To test this, the amplitude values of compatible trials in a 50 ms
time-window centered around the most negative (and positive) peaks
between 100 and 150 ms (and 150–200 ms) were entered to a repeated
measures ANOVA with the factors ‘group’ and ‘electrode’ (Fz, Cz, Pz).
Finally, to investigate detrimental effects of chemotherapy on ERPs,
we investigated the N2 and the P300 in the stimulus-locked averages.
After rejection of eye and muscle artifacts, epochs of 100 ms before and
924 ms after the response were extracted from the continuous EEG and
baseline-corrected using a −100–0 ms pre-response window following
previously validated methodology (U.M. Kramer et al., 2007). To probe
the N2 incompatibility effect for group differences, we entered the
mean amplitude value between 180 and 280 ms (100 ms time-window
centered around the peak of the grand average N2) into a three-way
repeated-measures ANOVA that included the between-subject variable
‘group’ and two within-subject factors: ‘compatibility’ (compatible, in-
compatible) and ‘electrode’ (Fz, Cz). Moreover, the P300 was defined as
the most positive peak between 350 and 450 ms and its amplitude was
considered the mean voltage between 350 and 450 ms post stimulus-
onset. Latencies of the P300 were entered to a two-way repeated-
measures ANOVA on ‘group’ and ‘electrode’ (Cz, Pz), while the ampli-
tude values were included in a three-way repeated-measures ANOVA on
‘group’, ‘compatibility’ (compatible, incompatible) and ‘electrode’ (Cz,
Pz).
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Fig. 1. A. Grand averages of response-locked event-related potentials in ‘go’ trials at midline electrodes (Fz, Cz, Pz) for the three groups (controls, C+ group and C– group). Depicted are
ERPs for correct trials (dashed lines) and choice errors (thick solid lines). Data were bandpass filtered (bandpass 2–8 Hz) (U.M. Kramer et al., 2007). The grey shadows indicate the
interval where the difference between conditions is statistically significant. B. Three-dimensional isovoltage topographical maps for correct responses (left column) and choice errors
(right column) in the 50–150 ms interval for each group. Numbers below each map indicate the scale used.
Fig. 2. A. Grand averages of response-locked event-related potentials in ‘no-go’ trials at midline electrodes (Fz, Cz, Pz) for the three groups (controls, C+ group and C– group). Depicted
are ERPs for correct trials (dashed lines) and stop errors (thick solid lines). Data were bandpass filtered (bandpass 2–8 Hz). The grey shadows indicate the interval where the difference
between conditions is statistically significant. B. Three-dimensional isovoltage topographical maps for correct responses (left column) and stop errors (right column) in the 100–200 ms
interval for each group. Numbers below each map indicate the scale used.




Characteristics of the entire cohort are described in Table 1. There
were no significant differences between groups in age, gender, educa-
tion or grouped vascular risk factors. When analyzed independently,
only smoking history showed a significant difference between lung
cancer patients and HC (X2 (1, Yates continuity correction) = 11.4,
p < 0.001), but no differences were observed between both cancer
groups (C+ and C−).
3.2. Neuropsychological assessment
Both cancer groups exhibited a higher rate of cognitive impairment
(29% of C+ and 20% of C−) compared to healthy controls (X2 (1,
Yates continuity correction) = 1.78, p = 0.18) (see Table 2). Con-
cerning specific neuropsychological assessment, there were no differ-
ences between groups after applying Bonferroni correction. However,
uncorrected results showed that lung cancer patients performed sig-
nificantly worse than healthy controls in several subtests. Specifically
C+ patients performed worse than healthy controls in WAIS-III Voca-
bulary, in speed-processing and executive functions (Trail Making Test
part B and part B minus part A) as well as in visuospatial abilities (ROCF
first copy). C– patients performed worse than HC in working verbal
memory (AVLT immediate recall (A1)).
3.3. Neurophysiological correlates
3.3.1. Behavioral results
Behavioral data for each group is depicted in Table 3. The percen-
tage of correct responses, was significantly different between the groups
(F(2,47) = 9.9, p < 0.001). Games-Howell post hoc tests revealed that
control subjects (mean ± SD: 84.2 ± 19.3%) responded more accu-
rately than the C+ group (61.1 ± 19.3%) and the C– group
(56.8 ± 19.3%) (p = 0.03 and p = 0.01 respectively). In line with
previously reported results applying the usual Flanker task, a main ef-
fect of ‘compatibility’ (F(1,47) = 18.6, p < 0.001) showed that the
percentage of errors 13.6 ± 11.0%, was higher for incompatible trials
(15.4 ± 12.7%) than for compatible trials (10.9 ± 9.7%). A sig-
nificant difference across groups was found in the percentage of errors
(F(2,47) = 6.1, p = 0.005). Games-Howell post hoc tests revealed a
trend towards significance with controls (7.1 ± 9.7%) committing less
errors than the C+ group (18.3 ± 9.7%) (p = 0.007) and the C–
group (14.6 ± 9.7%) (p = 0.04). Furthermore, the percentage of
corrected errors did not differ across groups (F(2,47) = 2.6, p = 0.09).
Regarding reaction time measures, errors (392 ± 112 ms) were
faster than correct responses (479 ± 60 ms) (F(1,47) = 30.5,
p < 0.001) and correct responses were faster in compatible trials
(470 ± 66 ms) than in incompatible trials (492 ± 77 ms) (F(1,47)
= 7.8; p = 0.007), as expected, with no differences between groups.
Lastly, RTs in corrected errors (304 ± 74 ms) were faster than in non-
corrected errors (431 ± 193 ms) (F(1,47) = 17.2, p < 0.001) and no
differences were found between groups.
Despite remarkably different means in each group, the post error
slowing (global mean ± SD: 16 ± 102 ms), post non-inhibited
slowing (30 ± 67 ms) and the SSRT (309 ± 76 ms) did not differ
between groups, mainly due to their large variability (see Table 3).
3.3.2. Event-related potentials (ERP)
Both choice and stop errors led to a negative component peaking
after the error, resembling the well-known ERN component with its
characteristic frontal central distribution (Falkenstein et al., 1990;
Gehring et al., 1993) while the correct responses yielded a more ante-
rior negative deflection (CRN) localized at Fz (see panel A, Figs. 1 and
2). The choice ERN peaked at ≈100 ms after the response, whereas the
stop ERN peaked slightly later at ≈150 ms after the response (see U.M.
Kramer et al. (2007)). Results for both conditions will be reported se-
parately.
3.3.2.1. ERPs: response-locked data
3.3.2.1.1. ‘Go’ trials: choice ERN. For illustrative purposes, ERPs of
correct responses, choice errors and the difference waveforms have
been plotted for each group at midline locations (Fz, Cz and Pz
electrodes) (see Fig. 1A). Likewise, isovoltage topographical maps for
choice errors in the 50–150 ms interval are depicted separately for each
group (see Fig. 1B).
Differences in the choice CRN and choice ERN between the groups
were reflected by a significant main effect of group (F(2,47) = 3.9,
p = 0.03) and post hoc Tukey's tests showed that the healthy control
and the C– groups differed significantly (p = 0.05), with healthy con-
trols showing a more negative amplitude overall (−1.8 ± 1.7 μV)
than the C– group (0.3 ± 1.2 μV). Likewise, the interaction of ‘elec-
trode’ by ‘response’ (correct vs. error trials) (F(2,47) = 32.8,
p < 0.001) indicated that the ERN effect was larger at central regions,
where the difference between the ERN and CRN is larger than at frontal
sites [mean CRN and ERN values across groups at Fz (CRN:
−1.4 ± 2.1 μV; ERN: −1.3 ± 2.8 μV) and at Cz (CRN:
0.1 ± 1.4 μV; ERN: −0.8 ± 2.8 μV)].
The significant interaction of electrode by response by group (F
(2,47) = 4.1, p = 0.02) showed that the amplitude of the ERN and
CRN components differed depending on the electrode and the group
(see difference waveforms in Fig. 4A). This interaction reflects the
differential amplitude observed across groups in the negativity asso-
ciated with erroneous responses (see Fig. 3B). While the ERN compo-
nent (see difference waveform, Error – Correct) is clearly observed at Cz
location in the control group and as expected considering previous
studies, the amplitude is drastically diminished in the other two groups
(C+ and C−).
To further analyze this interaction we conducted independent
sample t-tests comparing the difference ERN (ERN – CRN) at Cz be-
tween each pair of groups. Healthy controls were found to show a
greater difference between errors and correct trials compared to the C–
group (t(31) =−2.9, p = 0.007) (HC: −2.0 ± 1.7 μV; C−:
−0.3 ± 1.7 μV). The remaining main effects and interaction did not
reach significance.
3.3.2.1.2. ‘No-go’ trials: stop ERN. For the sake of illustration, ERPs
of correct responses, stop errors and the difference waveforms have
been plotted for each group and Fz, Cz and Pz electrodes separately (see
Fig. 2A). Furthermore, isovoltage topographical maps for stop errors in
Table 1
Baseline demographics and vascular risk factors of the entire cohort.
C+ (n = 17) C– (n = 15) HC (n = 18) p-Value
Age (years)a 61.69 ± 7.67 57.44 ± 3.43 62.12 ± 8.10 0.30
Gender (F/M) 2/15 0/15 0/18 0.13
Education (years)b 6 (4,17) 7 (4,14) 8 (6,19) 0.30
KPSb 80 (70,90) 80 (70,100) 100 (90,100) 0.0001
Smokingc 17 (100) 15 (100) 11 (61) 0.001
Alcoholc 6 (35) 5 (33) 11 (61) 0.19
Hypertensionc 5 (29) 6 (40) 8 (44) 0.65
DM type IIc 5 (29) 4 (27) 1 (5) 0.16
Dyslipidemiac 5 (29) 6 (40) 10 (55.5) 0.29
Vascular risk factorsc
Low-risk (0 or 1) 8 (47) 2 (13) 6 (33) 0.12
High-risk (≥2) 9 (53) 13 (87) 12 (66)
C+: chemotherapy-treated small-cell lung cancer group; C−: non-chemotherapy treated
non-small cell lung cancer group; HC: healthy control group; F: female; M: male; KPS:
Karnofsky performance status; IQ: intelligence quotient; DM: diabetes mellitus.
Statistically significant results are marked in bold.
a Mean ± SD.
b Median (range).
c n (%).
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the 100–200 ms interval have been plotted for each group (see Fig. 2B).
In line with the results obtained for the choice errors, differences in
the CRN and stop ERN between the groups were reflected by a sig-
nificant main effect of group (F(2,47) = 4.6, p = 0.02) and post hoc
Tukey's tests showed that controls and the C– group differed sig-
nificantly at p = 0.01 with controls showing a more negative amplitude
overall (−2.1 ± 3.1 μV) than the C– group (−0.1 ± 3.4 μV).
Moreover, the main effect of ‘response’ (F(1,47) = 40.0, p < 0.001)
showed a clear negativity in erroneous stop trials when compared to
correct trials (ERN: −2.2 ± 2.8 μV; CRN: 0.08 ± 1.4 μV). The
interaction of ‘electrode’ by ‘response’ (F(2,47) = 42.5, p < 0.001)
showed the different scalp distribution of the ERN and CRN (larger
negativity for the CRN in frontal regions; similar values for the ERN in
frontal and central locations) [mean values of CRN (Fz:
−0.5 ± 1.4 μV; Cz: 0.7 ± 1.4 μV) and ERN (Fz: −2.1 ± 2.9 μV; Cz:
−2.2 ± 3.2 μV)]. As in the case of choice errors, the interaction of
‘response’ by group (F(2,47) = 3.4, p = 0.04) and ‘electrode’ by ‘re-
sponse’ by group (F(2,47) = 3.4, p = 0.04) showed that the amplitude
of the difference ERN (error vs. correct trials) was larger for the control
group mainly at Cz when compared to both patient groups (see
Table 2
Summary of neuropsychological evaluation.
C+ (n = 17) C– (n = 15) HC (n = 18) p-Value
Cognitive impairmentc 5 (29%) 3 (20%) 1 (6%) 0.18
Mattis dementia rating scale-2a 144 (133–144) 144 (140–144) 144 (139–144) 0.91
BDI (≥13)c 5 (29) 4 (27) 2 (11) 0.30
Estimated verbal IQ
WAIS-III vocabulary sub-test 0 ± 1.03⁎ 0.21 ± 0.73 1.05 ± 1.13 0.01
Language
Brief Spanish adaptation of the Boston naming test 0.33 ± 0.86 0.25 ± 0.59 0.56 ± 0.68 0.59
Verbal fluency
Semantic fluency 0.43 ± 0.70 0.28 ± 0.65 0.30 ± 0.76 0.67
Phonemic fluency −0.33 ± 1.23 −0.23 ± 1.12 0.5 ± 0.72 0.05
Processing speed/executive functions
Trail Making test A (TMT-A) −0.45 ± 0.87 −0.08 ± 0.72 0.31 ± 0.97 0.06
Trail Making test B (TMT-B) −0.83 ± 0.82⁎ −0.41 ± 0.99 −0.02 ± 0.75 0.04
TMT-B minus TMT-A (in seconds)a 144 ± 96⁎ 112 ± 118 66 ± 45 0.02
Attention/working memory
WAIS-III digits sub-test 0.15 ± 1.12 0.28 ± 0.57 0.65 ± 0.80 0.20
Visuospatial abilities
ROCF first copy 0.60 ± 1.05⁎ 1.23 ± 1.24 1.68 ± 1.03 0.03
Visual memory
ROCF delayed 0.43 ± 0.80 1 ± 0.97 0.78 ± 0.73 0.26
Verbal memorya
AVLT immediate recall (A1) 4.06 ± 2.01 3.43 ± 1.28⁎⁎ 5.06 ± 1.62 0.03
AVLT immediate recall (B) 4.50 ± 0.85 4.86 ± 1.77 5 ± 1.37 0.60
AVLT short-delay recall(A6) 5.86 ± 1.61 6.71 ± 3.45 7.72 ± 3.23 0.23
AVLT long-delay recall(A7) 5.38 ± 2.55 6.21 ± 3.11 7.39 ± 3.52 0.29
All results are z-scores mean ± SD except for araw score, bmedian (range), cn (%).
C+: chemotherapy-treated small-cell lung cancer group; C−: non-chemotherapy treated non-small cell lung cancer group; HC: healthy control group; BDI: Beck Depression Inventory
test, IQ: intelligence quotient, WAIS-III: Wechsler Adult Intelligence Scale-III, ROCF: Rey-Osterrieth Complex Figure, AVLT: Auditory Verbal Learning Test.
Statistically significant results are marked in bold.
⁎ Significant differences were between C+ and HC.
⁎⁎ Significant differences were between C– and HC.
Table 3
Summary of behavioral and ERP results.
C+ (n = 17) C– (n = 15) HC (n = 18) p-Value
RT (compatible) 465.7 ± 63.9 476.1 ± 84.6 467.6 ± 52.5 0.89
RT (incompatible) 490.2 ± 84.8 499.8 ± 95.9 486.5 ± 51.1 0.89
RT difference 24.5 23.7 18.9
Percentage of choice errors 18 ± 13⁎ 15 ± 11⁎⁎ 7 ± 4 0.005
RT (choice errors) 286.0 ± 84.3 302.2 ± 75.4 323.4 ± 61.5 0.33
Percentage of corrected errors 31 ± 25 33 ± 25 48 ± 23 0.09
Post-error slowing −19.3 ± 112.6 8.8 ± 86.4 66.4 ± 84.0 0.11
Percentage of inhibited no-go 41.5 ± 15.3 47.5 ± 13.5 48.9 ± 9.3 0.20
Post-non-inhibition slowing 18.3 ± 44.5 31.6 ± 62.4 38.8 ± 84.6 0.69
Stop-signal delay 121.9 ± 82.4 135.2 ± 68.7 161.0 ± 51.7 0.24
SSRT 334.1 ± 104.8 300.6 ± 51.7 292.5 ± 51.9 0.24
Percentage artifact rejections 26.5 ± 23.6 22.0 ± 19.4 22.4 ± 21.0
Included choice errors 123.3 ± 94.7 106.2 ± 57.9 56.6 ± 31.5
Included stop errors 72.9 ± 37.3 74.2 ± 32.5 77.7 ± 17.7
RT: reaction time of correct responses in milliseconds; percentage of choice errors: percentage of error trials of all ‘go’ trials; percentage of corrected errors: number of corrected ‘go’ errors
relative to all choice errors; percentage of artifact rejection: average percentage of rejected EEG epochs; included ‘go’ and stop errors: the average number of included error trials after
artifact rejection; SSRT: stop-signal reaction time; C+: chemotherapy-treated small-cell lung cancer group; C−: non-chemotherapy treated non-small cell lung cancer group; HC: healthy
control group.
Statistically significant results are marked in bold.
⁎ Significant differences were between C+ and HC.
⁎⁎ Significant differences were between C– and HC.
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difference waveforms in Fig. 4A/B). Analogous to the analysis per-
formed in choice errors, to further analyze the interaction we conducted
independent sample t-tests comparing the difference ERN (ERN – CRN)
at Cz between each pair of groups. As in choice errors, healthy controls
were found to show a greater difference between errors and correct
trials compared to the C– group (t(31) =−3.1, p = 0.005) (HC:
−4.5 ± 2.7 μV; C−: −1.6 ± 2.6 μV). Neither the interaction of
‘electrode’ by group nor the remaining effects did reach significance.
3.3.2.2. ERPs: stimulus-locked data. Stimulus-locked averages are
depicted in Fig. 5. Visual inspection did not show large amplitude
differences between groups except for enlarged amplitude in the N2
component for the C+ and C– patient groups (Fig. 5A/B).
N1/P2: As expected, no group differences were found in the am-
plitude of the N1 (F(2,47) = 0.2, p = 0.9) (HC: −1.7 ± 2.6 μV; C+:
−1.7 ± 2.7 μV; C−: −1.8 ± 2.9 μV) or in the P2 component (F
(2,47) = 0.3, p = 0.7) (HC: 0.7 ± 4.0 μV; C+: 0.5 ± 4.2 μV; C−:
0.0 ± 4.4 μV). The interaction terms did not reached significance ei-
ther (see Fig. 1).
N2: In contrast to the apparent enhancement of the N2 for the C+
and C– patient groups (Fig. 5B), and probably due to the large varia-
bility observed, no differences between groups were found in the am-
plitude of this component (F(2,47) = 1.3, p = 0.3) (HC:
−0.1 ± 5.0 μV; C+: −1.7 ± 5.2 μV; C−: −1.2 ± 5.5 μV) and no
other effects emerged.
P300: Regarding the peak latency of the P300 component, no dif-
ferences between groups were found (F(2,47) = 0.4, p = 0.6) nor the
remaining effects reached significance. The ANOVA on the P300 am-
plitude revealed a main effect of compatibility (F(2,47) = 6.5,
p = 0.01) denoting a larger P300 for compatible (2.1 ± 2.7 μV) than
for incompatible stimuli (1.7 ± 2.5 μV). No group differences were
found (F(2,47) = 1.1, p = 0.4) and no other effects were significant.
Overall, stimulus-locked ERP components did not differ across
groups, ruling out the possibility that the effects above observed in
response-locked averages could have been affected by overall ampli-
tude differences across groups.
4. Discussion
Cognitive control can be tested by using paradigms exploring error
monitoring and error compensation mechanisms. The ERN has been
previously described as a neurophysiological marker of error detection,
showing alteration in aging and several neurodegenerative diseases.
The current investigation is the first exploring the ERN component in a
lung-cancer population. Our main goal was to study differences in
performance monitoring in a small-cell lung cancer group (SCLC, C+)
after chemotherapy, a non-small cell lung cancer patient group (NSCLC,
C−) prior to chemotherapy and a healthy control group (HC). We
found that both lung cancer patients, and specially the C– group, ex-
hibited lower overall accuracy as well as a reduced difference between
both choice and stop CRN and ERN, indicating potential error mon-
itoring deficits in lung cancer patients both prior and following che-
motherapy.
ERN is considered to be an electrophysiological marker of error
detection originated in the medial prefrontal cortex, most probably the
anterior cingulate cortex (ACC) and supplementary motor regions
(Holroyd and Coles, 2002; Falkenstein et al., 1991). Further contribu-
tions from fronto-striatal circuits in the elicitation of error-related sig-
nals have been confirmed using functional MRI (Marco-Pallares et al.,
2009; Ullsperger and von Cramon, 2001) and lesion data (Gehring and
Fig. 3. A. Grand averages of response-locked difference waveforms
in ‘go’ trials (choice errors – correct trials) at midline electrodes (Fz,
Cz, Pz) for each group (Controls: solid line, C+ group: dashed line,
and C– group: dotted line). The grey shadows indicate the time in-
terval used to define the ERN and CRN amplitudes (50–150 ms). B.
Box plot illustrating the amplitude in correct trials and choice errors
in the 50–150 ms interval for each group.
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Fig. 4. A. Grand averages of response-locked difference waveforms
in ‘go’ trials (stop errors – correct trials) at midline electrodes (Fz,
Cz, Pz) for each group (controls: solid line, C+ group: dashed line,
and C– group: dotted line). The grey shadows indicate the time in-
terval used to define the ERN and CRN amplitudes (100–200 ms). B.
Box plot illustrating the amplitude in correct trials and stop errors in
the 100–200 ms interval for each group.
Fig. 5. A. Grand averages of stimulus-locked event-related potentials at midline electrodes (Fz, Cz, Pz) for the three groups (controls, C+ group and C– group). Depicted are ERPs for
compatible trials (thick solid lines), incompatible trials (dashed lines) and the difference waveforms (thin solid lines). Data were lowpass filtered (30 Hz). The grey shadows indicate the
interval where the difference between conditions is statistically significant. B. Grand averages of stimulus-locked event-related potentials in incompatible trials at midline electrodes (Fz,
Cz, Pz) for each group (controls: solid line, C+ group: dashed line, and C– group: dotted line). C. Grand averages of stimulus-locked event-related potentials at midline electrodes (Fz, Cz,
Pz) pooling together the three groups. Depicted are ERPs for compatible trials (thick solid lines), incompatible trials (dashed lines) and the difference waveforms (thin solid lines). The
grey shadows indicate the interval where the difference between conditions is statistically significant.
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Knight, 2000; Turken and Swick, 2008; Ullsperger et al., 2002;
Ullsperger and von Cramon, 2006; Stemmer et al., 2004). Recently,
error-related activity has been associated not only to the widely re-
cognized ACC but also to frontal and parietal cortex as well as sub-
cortical and cerebellar regions (see for review, Neta et al. (2015)). A
second but smaller ERN-like medial-frontal negativity related to re-
sponse monitoring can also be elicited after correct responses (CRN)
(Ford et al., 1999; Falkenstein et al., 2000). In contrast to the ERN, and
being less studied, the CRN presumably plays a more general role in
performance monitoring, maybe associated to the amount of un-
certainty in response monitoring and the initiation of future perfor-
mance adaptation or implementation of remedial actions (Falkenstein
et al., 2000; Bartholow et al., 2005; Sebastian-Galles et al., 2006).
Both performance monitoring and adaptation effects have been
shown to be more difficult with aging (Band and Kok, 2000; Eppinger
et al., 2007). Several studies reported reduced ERN amplitudes in
healthy older individuals compared to younger adults (Band and Kok,
2000; Falkenstein et al., 2001; Hoffmann and Falkenstein, 2011;
Schreiber et al., 2011) and also in patients with neurodegenerative
diseases (Mathalon et al., 2003; Ito and Kitagawa, 2005; Pietto et al.,
2016). In fact, it has been proposed that the larger the difference be-
tween the ERN and CRN components, the better the performance in
cognitive testing (Thurm et al., 2013). In this sense, increases in the
amplitude of the CRN in older adults could be observed in several
studies (Schreiber et al., 2011; Thurm et al., 2013; Endrass et al., 2012;
Eppinger et al., 2008), suggesting an impairment in the flexible adap-
tation to conflict processing related to aging (Eppinger et al., 2008).
Furthermore, Gehring and Knight (2000) observed equal amplitude for
the ERN and CRN in patients with focal lateral prefrontal cortex lesions,
resulting also in no difference between error and correct trials com-
ponents. Lateral prefrontal damage has also been associated to reduced
ERNs (Ullsperger et al., 2002; Ullsperger and von Cramon, 2006; Kopp
et al., 2014) as well as lesions in the thalamus (Seifert et al., 2011),
frontal white matter (Hogan et al., 2006), and basal ganglia (Ullsperger
and von Cramon, 2006). More recently, some studies focused in aging
and mild cognitive impairment described a persevered difference be-
tween ERN and CRN in older adults while it was diminished in cogni-
tive impaired patients (Thurm et al., 2013).
According to the previous literature, in the present study we ob-
served that both lung cancer patients, and specially the C– group, ex-
hibited a reduced difference between both choice and stop CRN and
ERN. While CRN remained stable through all groups, the ERN was
drastically diminished in both lung cancer groups. Since no differences
were observed across groups in stimulus-locked ERP components, this
result could not be due to overall reduction in ERP amplitude in pa-
tients due to their illness or medication (see Fig. 5). Additionally, the
CRN was larger in frontal regions while the ERN showed similar values
for frontal and central locations. Previous studies in lung cancer po-
pulation, also pre- and post-chemotherapy, described a functionally
impairment of the default mode network as well as functional and
structural changes in temporal and cerebellar networks (Simo et al.,
2015; Simo et al., 2017). This findings thus evidence that lung cancer
patients prior to chemotherapy exhibit cognitive deficits associated
with structural and functional changes in subcortical diffuse brain re-
gions while, following chemotherapy, patients show grey and white
matter structural damage more focused in temporal regions bilaterally
(Simo et al., 2015; Simo et al., 2017).
Our study highlights potential deficits in performance monitoring
(executive functioning) of lung cancer patients prior and following
chemotherapy. In terms of behavioral performance, lung cancer pa-
tients showed lower overall accuracy when compared to the control
group. Notice however, that reaction times were very similar across
groups (see Table 3) facilitating the comparison of the ERP responses
across groups, but suggesting that the patient groups may be per-
forming in a different speed/accuracy trade off. Thus, it could be the
case that reducing response speed in the patient groups might have
diminished the amount of errors performed and the differences ob-
served when compared to the control group. Taken together, these
findings suggest potential error monitoring deficits in lung cancer pa-
tients both prior and following chemotherapy, compared to an age-
matched HC group.
One possible explanation for the diminished amplitude of the ERN
in lung cancer patients, as described in the aging literature
(Nieuwenhuis et al., 2002), is the potential degradation of error mon-
itoring processes associated to impoverished executive control (J.H.
Kramer et al., 2007). Lung cancer patients showed clear differences in
accuracy at the behavioral level (but being equally fast as HC), sug-
gesting that the diminished amplitude in the ERN component could be
related to a reduced accuracy in error monitoring processes. An alter-
native explanation might be that, in contrast to the elderly, lung cancer
patients are not able to compensate their reduced cognitive control
capacity by recruiting redundant cognitive control regions, and thus
their accuracy is reduced. However, it remains to be observed if pa-
tients, performing in a slower pace and reducing the amount of errors,
could induced an ERN component of equal amplitude as the one ob-
served in the control group. The strongest emphasis of the patient group
in speed vs. accuracy might have induced larger uncertainty and noise
in decision-related processes, thus impacting on patients' overall per-
formance monitoring abilities. This could explain also the lack of dif-
ferences (equal amplitude due to reduced ERN amplitude) observed
between the ERN and CRN in the patient groups as they might be
performing in a more stringent speed/accuracy trade-off regime. Im-
portant to this idea is the fact that no behavioral differences were ob-
served in other reliable measures of cognitive control included in the
present study. For example, no group differences were observed for the
reaction time between incompatible and compatible trials, post-error
slowing related processes or motor inhibition (by means of the per-
centage of inhibited trials and the speed of motor inhibition - SSRT)
(Marco-Pallares et al., 2008; J.H. Kramer et al., 2007; Barch et al.,
2009). Thus, the present findings speak in favor of certain selectivity in
the deficits observed in performance monitoring that do not extent to
all domains of cognitive control processes. Further research is needed in
this direction to understand the sources of the differences observed here
in performance monitoring in cancer patients.
Although we specially focused in the ERN because its relevance in
error detection and conflict monitoring, the frontocentral N2 compo-
nent also reflects the activation of the ACC during correct conflict trials
and prior to the response (Van Veen and Carter, 2002a). In fact, both
component have similar scalp distributions, strongly suggesting that
these two components could share similar neural sources (Van Veen
and Carter, 2002a; Gehring et al., 2012). There is also considerable
evidence showing that amplitude of the ERN is sensitive to the degree of
response conflict and consistent with its role in conflict monitoring
(Larson et al., 2014). Additionally, the P300 component has been as-
sociated to cognitive and executive functions including attention and
context updating in tasks that require stimulus evaluation and memory
updating (Ferdinand et al., 2015).
In our study no differences emerged between groups concerning the
frontocentral N2 and peak latency of the P300 components. Although
both lung cancer groups exhibited an apparent enhancement of the N2
amplitude and a diminished P300 in comparison to the healthy control
group, these differences did not reach a statistically significant
threshold. The lack of significant differences between groups in the N2
and the P300, might be explained by the fact that the present task (the
Eriksen flanker task) is highly demanding, very fast and a manual re-
sponse is always required. The inherent difficulty of the task might
explain the differences to other studies in which a diminished P300
amplitude has been observed in much less demanding tasks (e.g.,
oddball task) (Kreukels et al., 2005; Kreukels et al., 2006; Kreukels
et al., 2008a; Kreukels et al., 2008b; Heukrodt et al., 1988; Kam et al.,
2016). Increased N2 amplitudes in the patient groups could have been
associated to an increased conflict monitoring which might converge
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with a diminished amplitude in the P300 (amplitude reductions are
observed in more resource-demanding tasks). An alternative hypothesis
is the large variability observed in all groups which prevented to ob-
serve these effects at the statistical level.
Regarding cognitive deficits, around 20–30% of patients in both
lung cancer groups met criteria for cognitive impairment; however, the
neuropsychological profile was quite different. The C– group performed
worse than HC and C+ in long-term verbal memory, as has been pre-
viously described in cancer patients before the initiation of therapy
(Shilling et al., 2005; Wefel et al., 2004). Following treatment, and in
line with previous literature (Jim et al., 2012), the C+ group per-
formed worse than the HC group in visuospatial measures and verbal
phonemic fluency. Although cognitive changes associated with either
cancer or cancer treatment have been extensively recognized, the pa-
thogenesis of these neurocognitive changes remains unclear. In this
setting, several hypotheses have been proposed including the biology of
cancer, as well as common risk factors for the development of both
cancer and mild cognitive changes in normal aging (Ahles and Saykin,
2007).
Our study presents some limitations that should be taken into ac-
count. The cross-sectional design of the study may have limited the
possibility to clearly isolate the effect of chemotherapy from more
general cancer-related changes. However, our results suggest that the
cancer by itself may be associated with cognitive and functional defi-
cits. Supporting these findings, several studies have hypothesized that
the biology of cancer, the inflammatory response triggering neurotoxic
cytokines or common risk factors for the development of both cancer
and mild cognitive changes may be responsible for the cognitive decline
found in these patients (Ahles and Saykin, 2007).
To conclude, lung cancer patients prior to chemotherapy (C−,
cancer-related effect) and 1-month following chemotherapy (chemo-
induced) exhibited an abnormal pattern of performance monitoring,
suggesting that both cancer and chemotherapy have an impact on
cognitive functioning of lung cancer patients, being ERN an objective
laboratory tool sensitive to cognitive dysfunction in this population.
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